Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales ...

Genomics (TXG) closed the last trading session at $8.86, gaining 7.1% over the past four weeks, but there could be plenty of ...

10x Genomics (TXG) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.33 per share a year ago. These figures are ...

Investors in 10x Genomics Inc (Symbol: TXG) saw new options become available this week, for the May 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to ...

I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption ...

In my last 10x Genomics (NASDAQ:TXG) article, I discussed how the ticker had been under relentless selling pressure, dropping from $209 in June 2021 to around $20 at the time of publication.

Investors in 10x Genomics Inc (Symbol: TXG) saw new options become available today, for the January 2024 expiration. One of the key data points that goes into the price an option buyer is willing ...

The following article will discuss the smart money sentiment towards 10x Genomics, Inc. (NASDAQ:TXG). Video: Watch our video about the top 5 most popular hedge fund stocks. Hedge funds ...